Biocon Biologics Successfully Integrates Viatris' Biosimilars Business in North America Ahead of Planned Timeline

07 Sep, 2023

Biocon Biologics Successfully Integrates Viatris' Biosimilars Business in North America Ahead of Planned Timeline

On September 6, Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, proudly announced the successful completion of its integration of Viatris' biosimilars business in North America, encompassing the United States and Canada, effective from September 1, 2023. This strategic move comes after Biocon Biologics' acquisition of Viatris' global biosimilars business in November 2022, solidifying its leadership position in the global biosimilars industry and enabling comprehensive end-to-end solutions for patients and customers. The integration process involved meticulous planning and execution to ensure a seamless transition of partners, personnel, systems, and procedures.

Shreehas Tambe, CEO & Managing Director of Biocon Biologics Ltd, expressed satisfaction with the North America transition, marking it as the second phase of integrating Viatris' biosimilars business, following a successful integration in Emerging Markets and ahead of the planned schedule.

Biocon's biosimilar division emerged as a key driver of top-line growth in the April-June quarter of the fiscal year, with revenues doubling compared to the previous year. This remarkable performance was attributed to three pivotal biosimilar products that significantly expanded their presence in the United States, leading to a remarkable 60 percent increase in the company's top-line figures.

Biocon Biologics, serving over 5.7 million patients annually, boasts a comprehensive portfolio of in-market and in-development biosimilars across various therapeutic areas, including four in the United States and six in Canada. Additionally, the company maintains a robust pipeline comprising 20 biosimilar assets, encompassing insulins and monoclonal antibodies across multiple therapy areas.

Matthew Erick, Chief Commercial Officer – Advanced Markets at Biocon Biologics Ltd, stated that this milestone represents a commitment to providing patients, customers, and healthcare providers in North America with deep expertise, dedication, and ongoing investments to advance biosimilars across the entire value chain, from innovation to ensuring a robust global supply.